• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.

    7/8/24 3:49:29 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    LUCID DIAGNOSTICS INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    54948X109

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒ Rule 13d-1(b)
         
      ☐ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 54948X109

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ayrton Capital LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    4,955,698*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    4,955,698*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,955,698*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     

     

     
     

     

    CUSIP No. 54948X109

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    4,955,698*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    4,955,698*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,955,698*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    CO

     

     

     
     

     

    CUSIP No. 54948X109

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Waqas Khatri

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    4,955,698*(1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    4,955,698*(1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,955,698*(1)

     
    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%(2)

     
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     

     
     

     

    CUSIP No. 54948X109

     

    Item 1. (a). Name of Issuer:
         
        Lucid Diagnostics Inc.
         
      (b). Address of issuer’s principal executive offices:
         
       

    360 Madison Avenue, 25th Floor

       

    New York, NY 10017

         
         
    Item 2. (a). Name of person filing:
         
        Ayrton Capital LLC
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Waqas Khatri
         
        Address or principal business office or, if none, residence:
         
      (b). Ayrton Capital, LLC
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
        Suite #7, Grand Pavilion Commercial Centre
        802 West Bay Road
        Grand Cayman
        P.O. Box 10250
        Cayman Islands
         
        Waqas Khatri
        55 Post Rd West, 2nd Floor
        Westport, CT 06880
         
      (c). Citizenship:
         
        Ayrton Capital LLC – Delaware
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – Cayman Islands
        Waqas Khatri – United States
         
      (d). Title of class of securities:
         
        Common Stock, $0.001 par value
         
      (e). CUSIP No.:
         
       

    54948X109

     

     
     

     

    CUSIP No. 54948X109

     

    Item 3. If This Statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:
       
      Ayrton Capital LLC

     

      (a) ☐ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) ☐ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) ☐ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) ☒ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) ☐ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) ☐ Parent Holding Company or control person in accordance with § 240.13d-1(b)(ii)(G)
      (h) ☐ Savings Association as defined in § 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) ☐ Church plan that is excluded from the definition of an investment company under § 3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(ii)(J)
      (k) ☐ Group, in accordance with § 240.13d-1(b)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
        Ayrton Capital LLC – 4,955,698*(1)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 4,955,698*(1)
       

    Waqas Khatri – 4,955,698*(1)

         
      (b) Percent of class:
         
        Ayrton Capital LLC – 9.9%(2)
        Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B – 9.9%(2)
        Waqas Khatri – 9.9%(2)
         
      (c) Number of shares as to which Ayrton Capital LLC has:

     

      (i) Sole power to vote or to direct the vote   4,955,698*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   4,955,698*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Alto Opportunity Master Fund SPC – Segregated Master Portfolio B has:     ,
               
      (i) Sole power to vote or to direct the vote   4,955,698*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of  

    4,955,698*(1)

    ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .
               
      Number of shares as to which Waqas Khatri has:      
             
      (i) Sole power to vote or to direct the vote   4,955,698*(1) ,
               
      (ii) Shared power to vote or to direct the vote   0 ,
               
      (iii) Sole power to dispose or to direct the disposition of   4,955,698*(1) ,
               
      (iv) Shared power to dispose or to direct the disposition of   0 .

     

    *Shares reported herein represent Common Stock of Lucid Diagnostics Inc. (the “Issuer”) held by Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a Cayman Islands exempted company (the “Fund”). The Fund is a private investment vehicle for which Ayrton Capital LLC, a Delaware limited liability company (the “Investment Manager”), serves as the investment manager. Waqas Khatri serves as the managing member of the Investment Manager (all of the foregoing, collectively, the “Reporting Persons”).

     

     
     

     

    CUSIP No. 54948X109

     

    (1) Represents (i) 16,408 shares of Common Stock held by the Reporting Persons; and (ii) 4,939,290 shares of Common Stock issuable upon the conversion of certain convertible notes (the “Notes”) held by the Reporting Persons. The issuable shares of Common Stock related to the conversion of the Notes are subject to a 9.99% beneficial ownership blocker.

     

    (2) Based on (i) 44,667,304 shares of Common Stock of the Issuer that were outstanding as of December 31, 2023; and (ii) 4,939,290 shares of Common Stock issuable upon the conversion of the Notes held by the Reporting Persons.

     

    For the sake of clarity, the holdings of the Reporting Persons reported herein are as of December 31, 2023.

     

    By virtue of these relationships, the Reporting Persons may be deemed to have sole voting and dispositive power with respect to the shares owned directly by the Fund. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the shares for purposes of Section 13 of the Exchange Act 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of the Reporting Person’s pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      Not applicable

     

     
     

     

    CUSIP No. 54948X109

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Not applicable
       
     Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to § 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d- 1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      Not applicable
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    CUSIP No. 54948X109

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 8, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
         
      By: /s/ Waqas Khatri

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see § 18 U.S.C. 1001).

     

     
     

     

    CUSIP No. 54948X109

     

    Exhibit 1

     

    Joint Filing Statement

     

    Statement Pursuant to Rule 13d-1(k)(1)

     

    The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0.001 par value of Lucid Diagnostics Inc., beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    Dated: July 8, 2024 Ayrton Capital LLC
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member
         
      Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B
         
      By: /s/ Waqas Khatri
      Name: Waqas Khatri
      Title: Managing Member of Ayrton Capital LLC
         
      Waqas Khatri
       
      By: /s/ Waqas Khatri

     

     

     

    Get the next $LUCD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUCD

    DatePrice TargetRatingAnalyst
    12/27/2021$16.00Buy
    Ascendiant Capital
    12/15/2021$17.00 → $13.00Buy
    Needham
    11/8/2021$18.00Buy
    Canaccord Genuity
    11/8/2021$14.00Buy
    BTIG Research
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

      Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK, April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in

      4/24/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Lucid Diagnostics Inc.

      DEFA14A - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/30/25 4:17:10 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Lucid Diagnostics Inc.

      DEF 14A - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/30/25 4:15:30 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

      4/25/25 4:44:19 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

      Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

      12/27/21 6:21:16 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Needham reiterated coverage on Lucid Diagnostics with a new price target

      Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

      12/15/21 6:36:10 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

      Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

      11/8/21 10:16:23 AM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO O'Neil Shaun was granted 300,000 shares, increasing direct ownership by 57% to 826,763 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:56:17 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Aklog Lishan was granted 300,000 shares, increasing direct ownership by 26% to 1,466,627 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:46:26 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Director Sokolov Jacque J was granted 112,800 shares, increasing direct ownership by 133% to 197,460 units (SEC Form 4)

      4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

      2/21/25 5:36:21 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      12/12/24 4:30:32 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.

      SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      7/8/24 3:49:29 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Lucid Diagnostics Inc. (Amendment)

      SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

      2/20/24 4:45:37 PM ET
      $LUCD
      Medical/Dental Instruments
      Health Care

    $LUCD
    Financials

    Live finance-specific insights

    See more
    • PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, May 1, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ), PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Compa

      5/1/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

      Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's first quarter 2025 finan

      4/30/25 8:31:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies  Veris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch  PAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet Conference call and webcast to be held today, March 25th, at 8:30 AM EDT NEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital

      3/25/25 8:01:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care

    $LUCD
    Leadership Updates

    Live Leadership Updates

    See more
    • PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

      Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK, Sept. 16, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (NASDAQ:LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements.  As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVmed's holdings of Lucid common stock remain

      9/16/24 4:30:00 PM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • Lucid Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors

      Final closing yields total gross proceeds of $29.8 million from offering Mr. Matheis serves as President and CEO of Sentara Health, one of the largest not-for-profit integrated health systems in the U.S., which encompasses hospitals, a physician group, and an affiliated health plan NEW YORK, May 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company's long-time institutional investors, with gross proceeds of $11.6 million, bringing

      5/7/24 7:39:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care
    • PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President

      Manning Brings Vast Digital Health Experience Focused on Demonstrable Growth and Commercial Excellence NEW YORK, April 25, 2023 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced the appointment of Gary Manning to the newly created position of President, Veris Health. Mr. Manning reports directly to Lishan Aklog, M.D., PAVmed's Chairman & Chief Executive Officer and Veris' Executive Chairman.

      4/25/23 8:45:00 AM ET
      $LUCD
      $PAVM
      Medical/Dental Instruments
      Health Care